Cogent Biosciences, Inc. - COGT
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Mar 31, 2026 | SCHEDULE 13D/A | — | — | 5,503,418 | View |
| Mar 26, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Commodore Capital LP | 1.8% | 2,802,905 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Commodore Capital Master LP | 1.8% | 2,802,905 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Robert Egen Atkinson | 1.8% | 2,802,905 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Michael Kramarz | 1.8% | 2,802,905 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Kynam Capital Management, LP | 4.33% | 6,165,223 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Kynam Capital Management GP, LLC | 4.33% | 6,165,223 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Yue Tang | 4.33% | 6,165,223 | View |
| Jan 30, 2026 | SCHEDULE 13G/A | The Vanguard Group | 7.5% | 11,514,326 | View |
| Jan 22, 2026 | SCHEDULE 13D/A | — | 9.9% | — | View |
| Jan 21, 2026 | SCHEDULE 13G/A | BlackRock, Inc. | 6.5% | 11,370,224 | View |
| Jan 21, 2026 | SCHEDULE 13G/A | BlackRock, Inc. | 6.5% | 11,370,224 | View |
| Nov 17, 2025 | SCHEDULE 13D/A | — | 9.9% | — | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Paradigm BioCapital Advisors LP | 2.3% | 3,156,398 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Paradigm BioCapital Advisors GP LLC | 2.3% | 3,156,398 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Senai Asefaw, M.D. | 2.3% | 3,156,398 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Paradigm BioCapital International Fund Ltd. | 2.0% | 2,786,647 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Commodore Capital LP | 7.2% | 10,208,060 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Commodore Capital Master LP | 7.2% | 10,208,060 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Robert Egen Atkinson | 7.2% | 10,208,060 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Michael Kramarz | 7.2% | 10,208,060 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Point72 Asset Management, L.P. | 4.0% | 5,753,833 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Point72 Capital Advisors, Inc. | 4.0% | 5,753,833 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Steven A. Cohen | 4.0% | 5,753,833 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | TCG Crossover GP I, LLC | 4.8% | 6,798,162 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | TCG Crossover Fund I, L.P. | 4.8% | 6,798,162 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Chen Yu | 4.8% | 6,798,162 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Kynam Capital Management, LP | 5.54% | 7,886,172 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Kynam Capital Management GP, LLC | 5.54% | 7,886,172 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Yue Tang | 5.54% | 7,886,172 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.